Mutation Pattern Predicts Patients Likely To Fail TKI Therapy in CML

Share this content:
Among patients with chronic myeloid leukemia, the development of new somatic mutations predicts treatment failure with tyrosine kinase inhibitors.
Among patients with chronic myeloid leukemia, the development of new somatic mutations predicts treatment failure with tyrosine kinase inhibitors.

Among patients with chronic myeloid leukemia (CML), the development of new somatic mutations predicts treatment failure with tyrosine kinase inhibitors (TKIs), according to a study published in Blood.1

TKIs, which target the BRC-ABL fusion protein, have markedly improved the life expectancy of patients with CML. Some patients develop resistance to this class of drugs, though such resistance is not fully understood. For the present study, researchers evaluated whether preleukemic somatic mutations affect treatment effectiveness in CML.

Serial samples were obtained for 100 patients with CML; targeted deep sequencing was conducted to profile variants in 92 genes known to mutate in this disease setting.

A series of patterns were revealed through deep sequencing, the most salient of which is referred to as “Pattern 2,” and predicts that patients will fail TKI treatment if new mutations are acquired after treatment initiation.

RELATED: Lack of Cost-sharing Subsidies Reduces TKI Initiation and Adherence in CML

Persistence of mutations after therapy initiation does not, however, predict treatment failure.

The authors conclude that although mutation patterns differ greatly among patients, correlations were drawn that have clinical implications.

Reference

  1. Kim TH, Tyndel MS, Kim HJ, et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood. 2016 Oct 12. doi: 10.1182/blood-2016-04-708560 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters